Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials
Open Access
- 30 April 2009
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 94 (5) , 743-744
Abstract
Imatinib, a targeted inhibitor of the tyrosine kinase activity of the BCR-ABL oncoprotein, has demonstrated considerable efficacy in all phases of chronic myeloid leukemia (CML). [1][1] Recently, Palandri and colleagues reported on the long-term outcomes of patients with CML in accelerated phase[2][Keywords
This publication has 7 references indexed in Scilit:
- The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upHaematologica, 2009
- Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximabHaematologica, 2008
- R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO studyHaematologica, 2008
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upHaematologica, 2008
- Accelerated and blastic phases of chronic myelogenous leukemiaHematology/Oncology Clinics of North America, 2004
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002